Cutler Group LP acquired a new position in shares of Viewray Inc (NASDAQ:VRAY) in the first quarter, Holdings Channel reports. The fund acquired 10,380 shares of the company’s stock, valued at approximately $76,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of VRAY. Partner Fund Management L.P. increased its position in shares of Viewray by 140.4% in the fourth quarter. Partner Fund Management L.P. now owns 2,114,316 shares of the company’s stock valued at $12,834,000 after acquiring an additional 1,234,870 shares during the period. Elk Creek Partners LLC purchased a new position in shares of Viewray in the fourth quarter valued at about $7,323,000. Vanguard Group Inc. increased its position in shares of Viewray by 59.6% in the third quarter. Vanguard Group Inc. now owns 3,011,099 shares of the company’s stock valued at $28,183,000 after acquiring an additional 1,124,417 shares during the period. Broadfin Capital LLC increased its position in shares of Viewray by 246.6% in the fourth quarter. Broadfin Capital LLC now owns 866,500 shares of the company’s stock valued at $5,260,000 after acquiring an additional 616,500 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Viewray by 5,511.0% in the third quarter. JPMorgan Chase & Co. now owns 564,294 shares of the company’s stock valued at $5,282,000 after acquiring an additional 554,237 shares during the period.

A number of equities analysts have issued reports on the stock. BidaskClub upgraded shares of Viewray from a “sell” rating to a “hold” rating in a research report on Thursday. Cantor Fitzgerald set a $13.00 price target on shares of Viewray and gave the company a “buy” rating in a research report on Tuesday, May 28th. B. Riley reiterated a “buy” rating and set a $12.00 price target (down previously from $13.75) on shares of Viewray in a research report on Monday, March 11th. TheStreet upgraded shares of Viewray from a “d+” rating to a “c-” rating in a research report on Thursday, March 21st. Finally, ValuEngine upgraded shares of Viewray from a “hold” rating to a “buy” rating in a research report on Tuesday, February 19th. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $12.63.

Shares of VRAY stock opened at $8.40 on Monday. Viewray Inc has a 12 month low of $4.86 and a 12 month high of $13.21. The company has a market cap of $821.19 million, a price-to-earnings ratio of -8.57 and a beta of 1.20. The company has a debt-to-equity ratio of 0.47, a current ratio of 4.28 and a quick ratio of 3.21.

Viewray (NASDAQ:VRAY) last announced its earnings results on Thursday, May 2nd. The company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.12). Viewray had a negative net margin of 139.82% and a negative return on equity of 71.16%. The business had revenue of $20.30 million for the quarter, compared to analysts’ expectations of $20.40 million. During the same period in the prior year, the company posted ($0.11) earnings per share. The firm’s quarterly revenue was down 22.5% on a year-over-year basis. As a group, research analysts predict that Viewray Inc will post -1.02 earnings per share for the current year.

WARNING: This piece of content was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/cutler-group-lp-takes-position-in-viewray-inc-vray/3030001.html.

Viewray Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

See Also: Why is a lock-up period needed for an IPO?

Want to see what other hedge funds are holding VRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viewray Inc (NASDAQ:VRAY).

Institutional Ownership by Quarter for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.